


## Curriculum Vitae

<b>Name</b>	<b>Jin-Hee Ahn</b>	
<b>Current Position &amp; Affiliation</b>	<b>Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine</b>	
<b>Country</b>	<b>South Korea</b>	

### Educational Background

1989-1995	M.D. College of Medicine, Hanyang University, Seoul, Korea
1999-2001	Master of Science University of Ulsan College of Medicine, Seoul, Korea
2001-2003	PhD. University of Ulsan College of Medicine, Seoul, Korea

### Professional Experience

2003.03~2005.02	Fellowship Dep. of Hemato-Oncology, Asan Medical Center
2005.03~2010.03	Assistant Professor Dep. of Oncology, Asan Medical Center
2010.04~2016.03	Associate Professor Dep. of Oncology, Asan Medical Center
2012.03~2013.02	Visiting Scientist Dana-Faber Cancer Institute, Boston, USA
2016.04~Present	Professor Dep. of Oncology, Asan Medical Center

## Professional Organizations

Member, Korean Medical Association  
Member, Korean Association of Internal Medicine  
Member, Korean Cancer Association  
Member, Korean Society of Medical Oncology (KSMO)  
Member, Korean Cancer Study Group (KCSG)  
Member, Korean Breast Cancer Society (KBCS)  
Member, American Society of Clinical Oncology (ASCO)  
Member, European Society of Medical Oncology (ESMO)  
Member, Connective Tissue Oncology Society (CTOS)

## Main Scientific Publications

1. Lee HS, Kim HJ, Chung IY, Kim JS, Lee SB Lee JW, Son BH, Ahn SH, Kim HH, Seo JB, **Ahn JH** Gong GY, Lee SW, Kim NK, Ko BS. Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment. *Scientific reports 2021; 11: 3376*
2. Jeong H, Hong YS, Kim YH, Kim CW, Song SY, Song JS, Cho KJ, Kim JE, **Ahn JH**. The role and clinical effectiveness of multiline chemotherapy in advanced desmoplastic small round cell tumor. *Clinical Medicine Insights: Oncology 2021, 15: 1-7*
3. Kim JY, Jeon JY, Choi YJ, Choi JK, Kim SB, Jung KH, **Ahn JH**, Kim JE, Seo SY. Characteristics of metastatic brachial plexopathy in patients with breast cancer. *Supportive Care in Cancer. 2020, 28 (4): 1913*
4. Sohn BS, Jeong JH, **Ahn JH**, Jung KH, Kim JE, Sohn JH, Koh SJ, Seo JH, Lee KS, Kim SB. A pilot study on intermittent every other days of 5-dose filgrastim compared with single pegfilgrastim in breast cancer patients receiving adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. *Investigational New Drugs 2020, 38: 866*

5. Oh CR, Hong JH, Kim JH, Lee JS, Kim HS, Kim TW, **Ahn JH**, Kim JE. Real-world outcomes of pazopanib treatment in Korean patients with advanced soft tissue sarcoma: A multicenter retrospective cohort study. *Targeted Oncology* 2020, 15: 485
6. Park JH, **Ahn JH**, Kim JE, Jung KH, Gong GY, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim DH, Kim SB. Predictive role of TP53, PIK3CA and MLL2 in ER+ HER2+ breast cancer: Biomarker analysis of Neo-ALL-IN [NCT 01275859]. *Anticancer Research* 2020, 40: 5883
7. Gwark SC, Kim JS, Lee CH, Kim YH, Kim MS, Hong SW, Choi MY, Jeon BH, Kwon NJ, Kim KY, Kim Y, Chang S, Yu JH, Park JY, **Ahn JH**, Jung KH, Kim SB, Lee HJ, Gong GY, Lee SB, Chung KY, Ko BS, Kim HJ, Lee JW, Son BH, Ahn SH. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. *Scientific Reports* 2020; 10: 17466
8. Lee HS, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, **Ahn JH**, Jung KH, Kim SB, Lee HJ, Gong GY, Ahn SH, Lee SB. Is asymptomatic surveillance beneficial after standard treatment ? A 10-year survival analysis of recurrent BC patients by detection method or recurrence. *Breast Journal* 2020; 26: 556-559
9. Lee KM, Song JS, Kim JE, Lee H, Chung HW, Cho KJ, Lee JS, **Ahn JH**. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expression. *Eur J Surg Oncol* 2020 July 46: 1287-1293
10. Kim JJ, Seo S, Kim JE, Jung SH, Song SY, **Ahn JH**. Clinical outcomes of angiosarcoma: a single institution experience. *Cancer Commun* 2019 Aug 6; 39 (1)
11. Sohn BS, Jeong JH, **Ahn JH**, Jung KH, Kim JE, Sohn JH, Koh SJ, Seo JH, Lee KS, Kim SB. A pilot study on intermittent every other days of 5-dose filgrastim compared with single pegfilgrastim in breast cancer patients receiving adjuvant docetaxel. Doxorubicin and cyclophosphamide (TAC) chemotherapy. *Invest New Drugs* 2019 Nov 15 [Epub ahead of print]

12. Sim SH, Park IH, Jung KH, Kim SB, **Ahn JH**, Lee KH, Im SA, Im YH, Park YH, Sohn J, Kim YJ, Lee S, Kim HJ, Chae YS, Park KH, Nam BH, Lee KS, Ro J. Randomized phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). *Br J Cancer* 2019 Dec; 121(12): 985-990
13. Lee HS, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, **Ahn JH**, Jung KH, Kim SB, Lee HJ, Gong GY, Ahn SH, Lee SB. Is asymptomatic surveillance beneficial after standard treatment? A 10 year survival analysis of recurrent BC patients by detection method of recurrence. *Breast J* 2019 Sep 17 [Epub ahead of print]
14. Kim J, Jeong JY, Choi YJ, Choi JK, Kim SB, Jung KH, **Ahn JH**, Kim JE, Seo S. Characteristics of metastatic brachial plexopathy in patients with breast cancer. *Supportive care cancer* 2019 Jul 30 [Epub ahead of print]
15. Park JH, Lee HJ, Lee SB, **Ahn JH**, Kim JE, Jung KH, Gong G, Son BH, Ahn SH, Kim SB. Intrinsic prognostic impact of tumor infiltrating lymphocytes in systemically untreated patients with early stage triple negative breast cancer. *Anticancer Res* 2019 Jun; 39 (6): 3111-3119
16. Chae SY, Ahn SH, Kim SB, Han S, Lee SH, Oh SJ, Lee SJ, Kim HJ, Ko BS, Lee JW, Son BH, Kim J, **Ahn JH**, Jung KH, Kim JE, Kim SY, Choi WJ, Shin HJ, Gong G, Lee HS, Lee JB, Moon DH. Diagnostic accuracy and safety of  $16\alpha$  [ $^{18}\text{F}$ ] fluoro- $17\beta$ -oestradiol PET-CT for the assessment of estrogen receptor status in recurrent or metastatic lesions in patients with breast cancer. A prospective cohort study. *Lancet Oncol* 2019 Apr; 20 (4): 546-555
-